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Cyclophosphamide is an alkylating agent widely used for the treatment of malignant
neoplasia and which can be used in the treatment of multiple rheumatic diseases. Med-
ication administration errors may lead to its reduced efﬁcacy or increased drug toxicity.
Many errors occur in the administration of injectable drugs. The present study aimed at
structuring a routine for cyclophosphamide use, as well as creating a document with phar-
macotherapeutic guidelines for the patient. The routine is schematized in three phases:
pre-chemotherapy, administration of cyclophosphamide, and post-chemotherapy, taking
into  account the drugs to be administered before and after cyclophosphamide in order to
prevent adverse effects, including nausea and hemorrhagic cystitis. Adverse reactions can
alter laboratory tests; thus, this routine included clinical management for changes in white
blood cells, platelets, neutrophils, and sodium, including cyclophosphamide dose adjust-
ment in the case of kidney disease. Cyclophosphamide is responsible for other rare – but
serious – side effects, for instance, hepatotoxicity, severe hyponatremia and heart failure.
Other adverse reactions include hair loss, amenorrhea and menopause. In this routine, we
also  entered guidelines to post-chemotherapy patients. The compatibility of injectable drugs
with the vehicle used has been described, as well as stability and infusion times. The rou-
tine aimed at the rational use of cyclophosphamide, with prevention of adverse events andrelapse episodes, factors that may burden the health care system.Please cite this article in press as: Teles KA, et al. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
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Rotina  de  administrac¸ão  de  ciclofosfamida  em  doenc¸as autoimunes
reumáticas:  uma  revisão
Palavras-chave:
Ciclofosfamida
Antieméticos
Quimioterapia
Cistite
r  e  s  u  m  o
A ciclofosfamida é um agente alquilante vastamente usado para o tratamento de neoplasias
malignas e pode ser usado no tratamento de diversas doenc¸as reumatológicas. O erro de
administrac¸ão  de medicamentos pode levar à diminuic¸ão da eﬁcácia ou ao aumento da
toxicidade medicamentosa. Diversos erros ocorrem na administrac¸ão de medicamentos
injetáveis. O trabalho objetivou a estruturac¸ão de uma rotina do uso de ciclofosfamida, bem
como  a criac¸ão de um documento de orientac¸ões farmacoterapêuticas para o paciente. A
rotina foi esquematizada em três fases, a pré-quimioterapia, a administrac¸ão da ciclofos-
famida e a pós-quimioterapia, que levaram em considerac¸ão os medicamentos que devem
ser  administrados antes e depois da ciclofosfamida para prevenc¸ão aos efeitos adversos,
incluindo náusea e cistite hemorrágica. As reac¸ões adversas podem alterar os exames
laboratoriais e a rotina incluiu manejo clínico para alterac¸ão clínica dos leucócitos, das
plaquetas, dos neutróﬁlos e do sódio incluindo o ajuste de dose de ciclofosfamida em caso
de  insuﬁciência renal. A ciclofosfamida é responsável por outras reac¸ões adversas raras,
mas  sérias, como hepatotoxicidade, hiponatremia severa e falência cardíaca. Outras reac¸ões
adversas incluem perda de cabelo, amenorreia e menopausa. A rotina foi composta tam-
bém por orientac¸ões ao paciente pós-quimioterapia. A compatibilidade dos medicamentos
injetáveis com o veículo foi descrita, bem como o tempo de estabilidade e o tempo de infusão.
A  rotina visou ao uso racional da ciclofosfamida e prevenir os efeitos adversos e os episódios
de  recidiva, os quais podem onerar o sistema de saúde.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Cyclophosphamide (CPM) is an alkylating agent widely used
for the treatment of malignancies such as breast cancer,1
multiple myeloma,2 renal diseases including nephrotic syn-
drome refractory to corticosteroid and focal segmental
glomerulonephritis, and this drug can be used in the treat-
ment of multiple rheumatic diseases,3–5 including cicatricial
pemphigoid (also called pemphigoid mucous membrane),4
rheumatoid arthritis,5 juvenile dermatomyositis,6 systemic
sclerosis,7,8 interstitial lung disease,7 lupus vasculopathy,9
systemic vasculitis, and refractory treatment of lupus-
associated thrombocytopenic purpura.10 In addition to other
indications of cyclophosphamide, the treatment of neu-
romyelitis optica can also be included.11
In children, cyclophosphamide may be used in the
treatment of nephrotic syndrome and systemic lupus
erythematosus.12,13
Cyclophosphamide can be administered by oral or intra-
venous route.14 The intravenous administration is more
frequent in the ﬁeld of rheumatology, taking into account
studies showing an efﬁcacy similar to that of oral treat-
ment, but with less toxicity, for example, a decrease in
premature ovarian failure, less severe infection, and lower
overall exposure of the urinary tract to acrolein, a toxic
metabolite of cyclophosphamide.15 Cyclophosphamide is
orally administered QD (24–24 h), while the intravenous routePlease cite this article in press as: Teles KA, et al. Cyclophosphamide adm
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
is administered in pulses, and the dose is adjusted according
to hematologic and renal toxicities.16BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The administration of cyclophosphamide in pulses may
follow a weekly or monthly basis, in combination with
a corticosteroid and other chemotherapeutic agents, pro-
vided that the attending physician takes into account the
minimum blood count (NADIR) for the administration of
cyclophosphamide.16–18 Cyclophosphamide may cause some
adverse events, and when these effects are related to the drug,
are classiﬁed as an adverse drug reaction.19 The adverse drug
reaction can be conceptualized as an unintended and harmful
reaction into the body, occurring in those routinely used doses
in humans for prophylaxis, diagnosis, disease therapy, or for
changes of physiological functions.19
A reaction that occurs in a small percentage of the popu-
lation, but that, if not avoided, may cause irreversible damage
to the patient, such as death, congenital abnormalities, birth
defects or conditions that require permanent hospitalization,
is classiﬁed as “severe reaction”.19
Some adverse reactions related to the administration of
cyclophosphamide are bone marrow suppression, suscep-
tibility to infections, sterility and amenorrhea,18 as well
as nephrotoxicity and cystitis,18,19 and also cardiovascular
complications, for instance, sinus bradycardia, pericarditis,
myocarditis and heart failure.20 Children and adolescents
treated with high doses of cyclophosphamide are more  likely
to develop dental disorders and a decreased salivary ﬂow.
Cyclophosphamide is also teratogenic.21 A long term reaction
of cyclophosphamide is malignacies.18 One can observe aninistration routine in autoimmune rheumatic diseases: a review. Rev
increase in the incidence of bladder cancer and esophageal
and lung adenocarcionoma, which customarily occur after
two years of treatment.18
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In addition to adverse drug reactions of cyclophosphamide,
t is critical that the physician adopt all precautionary meas-
res, because these adverse reactions may be more  important
n cases where cyclophosphamide is administered intra-
enously, given that, with this route of administration, the
rug is not absorbed, the onset of its action is faster and,
ecause the drug does not undergo ﬁrst-pass metabolism, the
ioavailability, i.e. the bioavailable concentration to exert a
harmacological action, becomes proportionally higher ver-
us oral administration of cyclophosphamide.22,23 Another
mportant aspect to consider concerns the errors associated
ith the administration of injectable drugs.24
It is known that the use of injections is often associ-
ted with medication errors classiﬁed as serious events.22
ntravenous-route administration errors represent 21.1% of
ll errors, with possible risk of errors of contamination,
dministration rate, and dilution.25 Such parenteral drug
dministration errors, especially those by intravenous route,
an cause an adverse drug reaction.19
In addition to health-related problems, it is required that
he costs resulting from drug administration errors are taken
nto account. In Brazil, it is estimated that the annual cost
ith the use of chemotherapeutic drugs exceed 1.1 billion
eais, and this value can increase in cases of injectable drug
dministration errors.24
Thus, one must bear in mind that these costs may be mag-
iﬁed by the occurrence of adverse events.26 An adverse event
s any untoward medical occurrence that affects the patient
eing medicated, but without a direct causal relationship with
is/her treatment.19
Thus, it is important to standardize the administration of
arenteral drugs and provide their rational use, which can be
eﬁned as the patient’s need to receive the appropriate drug
n the correct dosage for an adequate length of time and with
he lowest cost.27
Taking into account the rational use of drugs, it is impor-
ant to standardize rules for the parenteral administration of
yclophosphamide. The objectives of this study are proposing
 cyclophosphamide administration routine in Rheumatology
nits, and the creation of a document containing pharma-
otherapeutic guidelines for the patient, in order to maximize
he efﬁciency of treatment based on a literature review.
ethods
yclophosphamide  routine
n infusion routine for cyclophosphamide was developed in
rder to increase the bioavailability (effectiveness) of this drug
hile minimizing adverse reactions, thus rendering the treat-
ent more  tolerable for the patient. The protocol was divided
nto stages to facilitate the comprehension of the health staff
nd the replication of the cyclophosphamide dosing sched-
le. The drugs of the ﬁrst (pre-ChT) and third (post-ChT)
teps correspond to the administration of pharmaceuticals inPlease cite this article in press as: Teles KA, et al. Cyclophosphamide adm
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
rder to prevent the main adverse reactions resulting from the
dministration of cyclophosphamide (second phase), includ-
ng nausea, vomiting, and hemorrhagic cystitis. The clinical
anagement of adverse reactions that change laboratory 6;x  x x(x x):xxx–xxx 3
tests was described, as well as the clinical management of
cyclophosphamide in renal failure. The rare, but serious,
adverse reactions were also highlighted.
The most common adverse reactions were emphasized
so that the attending physician could provide guidance with
respect to the main care that the patient should take in his/her
home, after administration of cyclophosphamide. These pre-
cautions are essential to prevent or minimize adverse effects
and increase treatment adherence.
In addition, the compatibility of these injectable drugs with
the vehicle, stability time, and infusion time was ascertained.
The sequence of administration of these drugs has been pre-
pared in order to increase the efﬁcacy of cyclophosphamide
and diminish the onset of adverse reactions to the drugs
administered.
Results
The routine administration of cyclophosphamide was devel-
oped in three phases: pre-ChT, cyclophosphamide admin-
istration, and post-ChT. With a view to the prevention of
hemorrhagic cystitis, intravenous hydration with a blood vol-
ume expander (a crystalloid: 0.9% saline) was standardized.28
In addition, the drug administration sequence, the amount
of diluent, the need (or otherwise) for dilution, infusion and
administration times, and laboratory tests which should be
monitored before and after the infusion of cyclophosphamide
were indicated, as well as the guidelines to the patient.
Fig. 1 3,5,20,29–42, lists the routine data, and Fig. 2 44–50
describes the guidelines for the patient. Severe and uncom-
mon  adverse reactions which should be monitored are
hepatotoxicity,3 hyponatremia45 (in this case, serum sodium
level = 135 mmol/L [sodium is an univalent element; thus,
1 mmol/L = 1 mEq/L)],45 and cardiovascular failure due to
cyclophosphamide cardiotoxicity.36
Other adverse reactions from cyclophosphamide are
amenorrhea,18 early menopause,46 and hair loss.3
Discussion
Drug administration errors can decrease the effectiveness
of the pharmacological treatment and increase both the
occurrence of adverse reactions and the ﬁnancial costs of
treatment.24 A retrospective study conducted in hospitals in
Spain between 2008 and 2010 evaluated the incidence of cost
and adverse event. 245,320 episodes were identiﬁed, with
an overall cost of 1,308,791.97 euros. Approximately 6.8% of
patients experienced adverse events, representing a rise of
16.2% in costs. Six of the ten adverse events that burdened
more  signiﬁcantly the hospital system occurred in the oper-
ating room, corresponding to an increase of expenses around
6.7% to the health system.26
A prospective study conducted between August and
November 1999 and between January and May 2000 noti-
ﬁed 1800 errors in 1663 patients. The number of notiﬁcationsinistration routine in autoimmune rheumatic diseases: a review. Rev
resulting from drug-related problems (including those proba-
ble and possible ones) was 215 (11.9%). Of these notiﬁcations,
108 (50.2%) were ﬁlled up due to adverse reactions, 100 (46.5%)
came out of therapeutic failure related to dosing, and seven
Please cite this article in press as: Teles KA, et al. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
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Cyclophosphamide administration routine in autoimmune rheumatic diseases
Pre-chemotherapy administration scheme
Hydration with saline (S)
In the case of congestive heart failure, hypertension, acute/chronic kidney disease, use glucose solution. The infusion time must be 3h.
Specified dose: 1000 mL/S 0.9%a
Dexamethasoneb,c
Dose:
Specified infusion: 1 hour/S 0.9%a
Specified time: 1 hour before cyclophosphamide
Time: 1/2 hour prior to cyclophosphamide
The use of mesna is controversial; it may be replaced by a suitable hydration.a
The administration of cyclophosphamide is carried out immediately after pre-QT phase, with a dose between 0.5 and 1 g/m2 body surface,f,g
diluted into 100-200 ml saline,h with an infusion time of 60-120 minutes.h
Mesna
The use of mesna is controversial; it may be replaced by a suitable hydration.a
Suggestion to interrupt cyclophosphamide treatment, according to
hematological parameters
Precautions and clinical management of cyclophosphamide with
respect to genitourinary system
Kidney failure  - clearance <10 mL/min: Reduce the dose
by 25%; supplementation with 50% after dialysis.m
Urinalysis - obtain a urinalysis every 4 weeks after administration
of cyclophosphamide because of the risk of hemorrhagic cystitis;n
watch for signs of hematuria, proteinuria, and leukocyturia.o
Mesna
Specified dose: 20 mg 
Specified dose: 20% of the dose of cyclophosphamidee
Dilution: 20 ml of Sd
Specified dose: 20 mg
Specified Infusion: 1-2 minute bolus
Specified time: immediately after cyclophosphamide
Time: 4 and 8 hours for IV use, or 2 and 6 hours for POe
Specified dose: 20% of the dose of cyclophosphamide (IV) or 40% of the
PO dosee
Dilution: 20 mL S in the case of IVd
Infusion: 15-30 minutes
Specified dose: 8 to 16 mg (VO)
Time: 6 and 14h after cyclophosphamide
Platelets  <100 000/mm3 k
Absolute neutrophil count  <1500 cells/µL l
White blood cell count  <3500/mm3 k
Infusion: 15-30 minutese
Time: 15 minutes prior to cyclophosphamidee
Dose:
Infusion: 10 minutes 
Dilution: 20 ml of S 0.9%d
Dose:
Dilution used:
Dose:
Dose:
Dilution used:
Infusion time:
Administration time:
Infusion time:
Ondansetronj
Noninvasive and invasive laboratory tests must be monitored in
patients receiving cyclophosphamide according to the severity of
their condition.
Noninvasive methods  - echocardiography, assessment of cardiac
function (systolic ejection and diastolic function, diastolic peak velocity
and atrial and valve function, electrocardiograms, electrocardiography,
24-hour Holter ECG).
Serious and uncommon adverse reactions should be monitored:
Hepatotoxicityqand hyponatremia. Serum sodium concentration in this
case is 135 mmol/L (sodium is an univalent element; thus, 1 mmol/L=1
mEq/L).r Cardiovascular failure due to cyclophosphamide cardiotoxicity.
Other adverse reactions from cyclophosphamide:
Amenorrhea,k premature menopause,g and hair loss. q
Invasive methods - magnetic resonance imaging, myocardial biopsy.p
Administration time:
Dose:
Administration time:
Infusion time:
Dosage scheme after chemotherapy
Furosemidei
Administration time:
Dilution used:
Infusion time:
Infusion time:
Administration time:
Administration time:
Fig. 1 – Cyclophosphamide administration routine in autoimmune rheumatic diseases.
Sources: aShepherd et al.29; bHawthorn; eCunningham30; cJordan et al.31; dTurner et al.32; eTrissel33; fHaubitz et al.34;
gMardegan et al.35; hDi Lisi et al.36; iSalido et al.37; jCalixto-Lima et al.38; kLotan et al.20; lZahn et al.39; mMilman40; nMota
et al.5; oMcDermid and Lönnerdal41; pCentro de Oncologia Unimed Birigui42; qSubramaniam et al.3; rMota et al.43
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Water intake - the physician should instruct the patient to drink at least two liters of water a day unless in the presence
of a kidney condition; thus, the amount of water to be consumed should be individualized. Imprensa electrolytes in the
blood.a
Instructions for preventing mucositis - cyclophosphamide can cause mucositis; some precautions are advisable and
these should be taken by the patient to minimize risks, including brushing adequately his/her teeth after a meal, using
a soft brush and a non-abrasive toothpaste (for children), avoiding alcohol and cigarettes, avoiding too much salt,
choosing soft foods, giving preference to food in the form of puddings, porridges, vitamins, gelatin, and caloric-,
protein-rich meat, chicken or fish soup.b,c
Clinical management for symptoms of nausea - the patient should eat before getting hungry, with small, frequent
(2-2 hours), slowly eaten meals  because hunger can increase nausea; also, should avoid very spicy, fatty and sweet
food and hot food and drinks. On the other hand, the patient should avoid drinking liquids during meals and should stay
away from the kitchen during food preparation, eating in a ventilated and pleasant environment.b
Guidelines for patients with anemia - the patient should consume foods of animal origin such as chicken, fish and
especially red meat, and should consume legumes and dark green vegetables such as kale, broccoli and spinach, pea
beans and other grains, and combine vegetables with sources of vitamin C (orange, mandarin [tangerine], lemon,
acerola). Milk, cheese, cottage cheese, yogurt and other dairy products should be avoided during or close to lunch or
dinner time.d,e
Guidelines for disposal of urine and faeces - on the appointed day to take cyclophosphamide and on the next two
days, when using the toilet the patient should flush three times with the cover closed. If someone else is responsible for
the cleaning of the patient’s excreta, this person should wear gloves and use disposable material. The cleaning
procedure must be done in a outside-inside manner; and all content should be placed in two plastic bags, which will
then be tightly closed. Cleaning should be completed with bleach.f,g
Guidelines for bathing - the patient must first wash his/her hands, then the face and head. Next, the stomach, back,
arms and the catheter (if in use of one of these devices).
Fig. 2 – Guidelines for the patient taking cyclophosphamide.
Sources: aInstituto Estadual de Hematologia Arthur de Siqueira44; bBruining et al.45; cGonzález et al.46; dOtero López47;
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3.3%) were due to intoxication. According to the criteria
modiﬁed) of Schumock and Tornton, 68.4% of drug-related
roblems are considered as preventable.47
The cyclophosphamide dosing schedule took into account
he most common adverse reactions, the administration’s
trategy in the case of kidney failure, and the sequence in
he administration of pre-ChT drugs, cyclophosphamide, and
ost-ChT drugs; to this end, the dosage of all medications
sed, their dilution and infusion time also were included.
The main clinical strategies in the face of adverse reactions
rom cyclophosphamide use included the care of hemor-
hagic cystitis, nausea, and vomiting.18 The administration of
hese drugs corresponds to what is deﬁned as a qualitative
olypharmacy, wherein the administration of a medication
s performed to correct the adverse reaction of another
edication.48
Several clinical strategies have been proposed to avoid
emorrhagic cystitis, including increased hydration of the
atient and the administration of mesna and furosemide.28,29
n those cases in which the patient suffers of a severe kidney
mpairment, it is preferable to administer mesna in place of
ydration, due to the patient’s water restriction.20,29
For the prevention of hemorrhagic cystitis, mesnaPlease cite this article in press as: Teles KA, et al. Cyclophosphamide adm
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
s administered in a dose equivalent to 60% of
yclophosphamide, divided into three doses – 20%
5 min  before the administration of cyclophosphamide,20% after cyclophosphamide, and 20% 4 or 8 h after
cyclophosphamide.28 Mesna reduces the deposit of acrolein
(a metabolite of cyclophosphamide) in the bladder, thus
preventing hemorrhagic cystitis and bladder cancer.18
In order to decrease the exposure of the urinary tract to
acrolein, the patient should be well hydrated before, during
and after the administration of cyclophosphamide. Thus, at
the time of his/her admission, the patient should receive,
through a venous access, 1 L of a blood volume expander (a
crystalloid: saline 0.9%) for 1 h, 60 min  before the administra-
tion of cyclophosphamide.51
Cyclophosphamide per se can be administered at any time.
In turn, the infusion of mesna depends on the administration
of cyclophosphamide.28 Mesna may be administered by oral
or parenteral (subcutaneous or intravenous) route.28
The oral administration of mesna has the advantage of
a convenient dosage schedule; however, its use brings some
disadvantages, for instance, a higher frequency of nausea
and vomiting.49,50 Another limiting factor of the use of this
drug orally is the decreased bioavailability versus parenteral
route, due to ﬁrst-pass metabolism, in addition to the potential
decrease in its absorption as a result of frequent episodes of
vomiting caused by the treatment with cyclophosphamide.31inistration routine in autoimmune rheumatic diseases: a review. Rev
Taking into account the concepts that guide the rational
use of pharmaceuticals, including the reduction of treatment
costs for both the patient and society, oral administration of
ARTICLE IN PRESSRBRE-331; No. of Pages 9
 l . 2 06  r e v b r a s r e u m a t o
mesna would have also the advantage of a likely decrease
in expenses, due the lower bed occupancy time and less
workload of the nursing team.51 Still in this context, another
possible disadvantage is the patient’s non-compliance; thus,
one cannot be sure that the patient has taken, or otherwise,
the last dose of mesna PO.52
The advantage of the use IV mesna is that there is no need
of absorption, and the onset of action of this drug is faster,
compared with oral administration.22,23,53 The disadvantage
of the parenteral route is the greater risk of contamination,
administration errors, less dosing convenience, and increase
of the patient’s hospital stay.23,53
However, mesna administration with a view to the pre-
vention of hemorrhagic cystitis in patients using cyclophos-
phamide in therapeutic doses for rheumatic diseases is
controversial; thus, mesna may be replaced by a suitable
hydration with 6 L of water per day, plus a diuretic drug, or
the use of hydration with a volume of 3 L/m2 per day.54
Furosemide is administered after cyclophosphamide infu-
sion at a dose of 20 mg,  in order to stimulate diuresis that,
in synergism with mesna, decreases the exposure of urothe-
lium to the action of acrolein.55 The maximum concentration
of furosemide is 10 mg/mL  administered in bolus, achieving
a therapeutic concentration of 10 mg/mL  per minute.55 The
second dose of mesna (20% of cyclophosphamide dose) is
administered in the interval between 15 and 30 min  after the
administration of cyclophosphamide.28
Nausea and vomiting are considered as common adverse
reactions in chemotherapy, and this also occurs with
cyclophosphamide31 which, in turn, participates of many
chemotherapeutic regimens. In this case, a routine has been
proposed for the treatment of rheumatic diseases. Nausea
caused by the exclusive administration of cyclophosphamide
(without a therapeutic scheme) is classiﬁed as a late-onset
nausea.56 Thus, ondansetron was not required to prevent this
effect.56 A decrease in effectiveness is another reason for not
using ondansetron prior to cyclophosphamide.57
This reduction in efﬁcacy occurs because ondansetron is an
inhibitor of CYP2B.58 This occurs because cyclophosphamide
is a prodrug that must be activated by CYP2B, resulting in
4-hydroxycyclophosphamide and aldophosphamide. These
metabolites are transported to the site of action, where they
undergo spontaneous cleavage, producing phosphoramide
mustard, responsible for the pharmacological effects of the
drug.58
Moreover, dexamethasone was added prior to chemother-
apy, as a prophylactic agent to anaphylactic shock and also
as an antiemetic.59 Preferably, dexamethasone should be
administered so that its peak coincides with the peak of
physiological corticosteroids, which normally occurs at 8 a.m.
and 16 p.m.58 A peak in dexamethasone plasma concentra-
tion occurs within 60 min, and its action begins in 30 min.55,60
Thus, the administration of dexamethasone should be started
in the morning, 30 min  before the administration of cyclophos-
phamide, preferably at 7:30 a.m.58
After the emesis caused by cyclophosphamide was clas-
56Please cite this article in press as: Teles KA, et al. Cyclophosphamide adm
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
siﬁed as a delayed-type, and in view of the decrease of
cyclophosphamide efﬁcacy when ondansetron is adminis-
tered prior to this chemotherapeutic agent, ondansetron (8 mg
PO31,61 administered at 6 and 14 or 8 and 16 h post-ChT, 1 6;x  x x(x x):xxx–xxx
and with a maximum dose of 16 mg  after chemotherapy, not
exceeding 32 mg  per day) was the last drug used for the pro-
phylaxis of emesis caused by cyclophosphamide.31
Other important adverse effects of cyclophos-
phamide include hematologic toxicity,18 kidney failure,20
hyponatremia,45,62 neurological impairment,45 amenorrhea,18
early menopause,46 hair loss,3 hepatotoxicity (rare),3 and
late-onset cancer.18 The dose of cyclophosphamide for
the treatment of systemic lupus erythematosus, including
those patients with neuropsychiatric and/or hematologic
disorders, with class IV lupus nephritis, and with other
serious manifestations of systemic lupus erythematosus,
is 0.5–1 g/m2 IV monthly,5,62 with dosage adjustment in
patients with hematological toxicity and kidney failure.20,63
Adverse hematologic reactions caused by cyclophosphamide
are classiﬁed as serious, as they cause high morbidity.19,64
NADIR is the minimum hematologic counting that must be
observed to see if the patient may or may not embark on
another chemotherapeutic cycle.65 The main hematological
tests include platelets, neutrophils, white blood cells and
neutrophil counts. Neutropenia is deﬁned as a decrease in
absolute neutrophil count <1500 cells/L.65 The main causes
of neutropenia include hematologic disorders, autoimmune
diseases, infection, adverse drug reaction, chemotherapy, and
radiotherapy.65 Thrombocytopenia occurs when the platelet
count is <100,000/mm3.65 In a patient with a platelet count
<81,000/mm3 concomitantly experiencing leukopenia, the
treatment should be discontinued until the platelet count
increase to 99,000/mm3.65 However, cyclophosphamide can
be used in the treatment of refractory thrombocytopenic
purpura, and in this case, among the hematologic disorders,
thrombocytopenia, and microangiopathic hemolytic anemia
are included. Leukopenia10 is deﬁned as a white cell count
<3500/mm3.65
Hepatotoxicity is an adverse reaction caused by cyclophos-
phamide that normally occurs at high doses.3 When
hepatotoxicity occurs at low doses, the reaction is classiﬁed as
a rare, but serious, event.19,64 Acute liver failure with low-dose
cyclophosphamide (200 mg)  was described in a case report
of a male Chinese aged 48 years with progressive glomeru-
lonephritis secondary to Wegener’s granulomatosis, 24 h after
the administration of cyclophosphamide.3 The diagnosis of
granulomatosis with polyangiitis was established by patho-
logical examination and c-ANCA.3 The patient was being
treated with high-dose methylprednisolone, plasmaphere-
sis, intermittent hemodialysis and low intravenous doses of
cyclophosphamide.3 Other factors that may be associated
with hepatotoxicity have been excluded, including antifun-
gals, HIV, and hepatitis B and C.3 Alanine transaminase
increased from 41 U/L to 336 U/L at the day of administration
of 200 mg  of cyclophosphamide; in the next day, a peak of
566 U/L was reached.3 Two weeks later, the patient was treated
with another pulse of 200 mg of cyclophosphamide (second
dose), and the concentration of alanine transaminase reached
1253 U/L.3 A liver biopsy was not possible, because the patient
had a clotting disorder.3 Another laboratory parameter to beinistration routine in autoimmune rheumatic diseases: a review. Rev
monitored is sodium concentration. Hyponatremia is consid-
ered as an electrolyte disorder identiﬁed in clinical practice.45
Although many  cases are mild or relatively symptomatic,
hyponatremia is regarded as a clinically important ﬁnding,
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ith high morbidity and mortality. Neurological symptoms of
yponatremia occur at sodium levels <125 mmol/L.66 Among
he complications of hyponatremia, one can mention central
ervous system disorders such as seizures, and even a per-
anent damage to the central nervous system, and death.66
yndrome of inappropriate antidiuretic hormone secretion
SIADH) was described in a case report in which this syndrome
as associated with the use of IV cyclophosphamide in a dose
f 500–1000 mg/m2, with a serum sodium level <120 mmol/L
n a patient presenting neurological complications.62
Cyclophosphamide may also cause cardiotoxicity. Rou-
inely, echocardiography, a noninvasive method, is used
o monitor cardiovascular function in patients treated
ith immunosuppressants.36 Other non-invasive methods
ost widely used are electrocardiography and 24-h (ECG)
olter monitoring.36 Invasive methods such as scintigraphy,
agnetic resonance imaging and cardiac biopsy are also
rocedures that can be used in cases of adverse reactions
lassiﬁed as serious.36
Other adverse reactions caused by cyclophosphamide
nclude amenorrhea, menopause, and late-onset cancer,
ncluding esophageal, lung and bladder adenocarcinoma.18,46
yclophosphamide was administered at a dose of
50–1000 mg/m2 body surface in LUMINA (Lupus in minori-
ies, nature versus nurture), a multicenter study performed
ncluding 567 women aged under 51 years.46 A decrease in
onadal function was found, and gonadal failure was deﬁned
s the occurrence of amenorrhea for more  than six months
ithout a history of hysterectomy.46 Cyclophosphamide has
lso been associated with teratogenicity.18
As to cyclophosphamide dose adjustment in patients with
idney failure, this is only done in severe cases, that is, with
 creatinine clearance <10 mL/min. The therapeutic regimen
f cyclophosphamide should be modiﬁed, its dose should be
educed by 25%, and supplemented with 50% after dialysis.34
The dilution of the drugs used in cyclophosphamide rou-
ine was carried out with the goal of maintaining the highest
ossible concentration of the drug in its non-ionized form.58
hus, two parameters were taken into account: drug compat-
bility with the vehicle (saline, dextrose or ringer lactate) and
ts stability time in the vehicle; preference was given to those
rugs whose stability time was longer, in order to ensure a
ore  effective treatment.33
When the drugs used have proved compatible and stable
ith the same vehicle, preference was given to the choice of
he same vehicle, as this facilitates their administration by
he nursing staff and prevents pharmacokinetic interaction,
hich would cause ionization of the drugs and a decrease in
heir efﬁcacy.67
Another important aspect that should be addressed is the
ducation of the patient on the treatment to what he/she is
eing submitted. A study in the city of Natal with 40 women
iagnosed with systemic lupus erythematosus at the Hospital
nofre has shown that patients showing greater adherence
ere those who  understood correctly the treatment and also
he disease; thus, these women satisfactorily understood thePlease cite this article in press as: Teles KA, et al. Cyclophosphamide adm
Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.09.008
dverse events and the clinical management, in order to min-
mize these adverse drug reactions.68
Publications on adverse events are important tools for
rug safety monitoring after their release for marketing
1 6;x  x x(x x):xxx–xxx 7
purposes by the health authorities of each country.69 This
review of medication administration intended to standardize
the administration of cyclophosphamide by health profes-
sionals, in order to minimize the adverse events caused by
drugs, the so-called adverse drug reaction.19
Conclusion
The routine was developed in order to increase the area under
the curve (AUC) for cyclophosphamide, and to attain an appro-
priate clinical management to minimize the adverse drug
reactions that, if not properly prevented, will cause dam-
age to the patient, for instance, an increased prevalence of
vomiting, and acrolein deposition in the bladder. The clinical
management of adverse reactions that alter laboratory tests
was described in order to guide the application of these tests.
Adverse reactions, even being rare, were highlighted because
these events can cause high morbidity. Thus, the rational use
of cyclophosphamide increases the safety of the treatment
and reduces the cost of administration of this chemothera-
peutic agent, since our goal is to avoid error.
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